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UNIT A3.1Metastatic Intra-Axial Neoplasia
Magnetic resonance imaging (MRI) is a sensitive noninvasive means by which to evaluate
intracranial pathology. The role of imaging in the metastatic work-up is to detect the
spread of tumor to the brain parenchyma, and define the location. Intravenous contrast
(gadolinium-DTPA) provides the greatest sensitivity for detecting brain lesions (Healy et
al., 1987) and is almost always indicated except when there is no intravenous access. This
unit presents the set of MR sequences used for imaging intra-axial brain metastases (see
Basic Protocol) and specific modifications will be discussed where necessary (see
Alternate Protocol). The sequences described in this unit are based on the authors’
experience with a 1.5 T scanner (Echospeed GE Medical Systems, Milwaukee, Wiscon-




RULE OUT (R/O) NON-HEMORRHAGIC METASTATIC DISEASE
The vast majority of metastases are located in the intra-axial supra-tentorial compartment,
are typically multiple and subcortical, and have a considerable amount of surrounding
vasogenic edema (Atlas and Lavi, 1996). In general, T1-weighted and T2-weighted images
provide tissue-specific information by elucidating the water content, hemorrhagic com-
ponents, and cellularity of lesions. Contrast enhancement of intra-axial brain lesions
indicates breakdown of the blood-brain barrier. Imaging following triple-dose MRI
contrast agent administration detects a greater number of small (<10 mm) metastatic
lesions than the standard dose (0.10 mmol/kg) (Yuh et al., 1995). Delayed imaging (10
to 30 min) after the administration of either the standard dose or high dose contrast
improves the detection of small metastatic lesions. In most institutions, patients receive
the standard dose and are scanned without any significant delay in the transverse and
coronal planes. Beyond generating a second plane of imaging, the coronal plane acquisi-
tion following the transverse sequence allows for a small delay (several minutes) follow-
ing intravenous contrast administration. In pediatric patients and other subjects requiring
sedation, the authors feel that a third post-contrast acquisition, in the sagittal plane, is
worthwhile in evaluating brain tumor patients. Sequences 1 to 5 comprise the preferred
protocol.
Table A3.1.1 lists the hardware necessary to perform the procedure, along with appropri-
ate parameters.
NOTE: Be sure that technologists and nurses have immediate access to any equipment
such as crash carts or oxygen that may be necessary in the event of an emergency.
Reactions to contrast agents are rare, but the resources are necessary.
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Table A3.1.1 Equipment Parameters for Imaging Brain Tumors
Coil type Quadrature head coil
Gradient coil strength 25 mT/m (or whatever the system permits)
Cardiac gating No
Peripheral gating For safety only
Respiratory gating No
Respirator If required by patient






Normal saline (0.9% NaCl), sterile
Intravenous contrast agent (e.g., Magnevist, Omniscan, or Prohance)
Set up patient and equipment
1. Interview (screen) the patient to ensure that he or she has no contraindications such
as cardiac pacemakers or other implants containing ferromagnetic materials. Also be
sure to find out if the patient has any health conditions that may require the presence
of special emergency equipment during the scanning procedure, or necessitate any
other precautions.
Generally, standard screening forms are used for all patients scanned in a magnetic
resonance system.
The presence of any ferromagnetic metals may be a health hazard to the patient when he
or she is inside the magnet, and will also affect the imaging. If in doubt as to the exact
composition of the items, it is best to exclude patients with any implants; see Shellock (1996)
for discussion of what implants may be safely scanned using magnetic resonance.
Patients may be accompanied into the magnet room by a friend or family member, who can
sit in the room during the scan and comfort the patient as needed. This companion must
be screened as well to ensure the absence of loose metal objects on the body or clothing.
2. If the procedure is a research protocol, have the patient sign any necessary consent
form.
3. Have the patient remove all jewelry and change into a gown to eliminate any metal
that might be found in clothing.
4. Have the patient wash off any mascara and other makeup to avoid local tissue heating
and image artifacts.
5. Inform the patient about what will occur during the procedure, what he or she will
experience in the magnet, and how to behave, including the following:
a. If earphones or headphones are used to protect the ears from the loud sounds
produced by the gradients, the patient will be asked to wear these, but will be able
to communicate with you at any time during the imaging.
b. The patient will be given a safety squeeze-bulb or similar equipment to request
assistance at any time (demonstrate how this works).
c. For good results the patient should not talk, and should avoid or minimize
swallowing or other movement, during each scan—i.e., as long as the banging
sounds continue. Between scans, talking and swallowing are allowed in most
cases, but should be avoided when comparative positional studies are being
performed; the patient will be informed when this is the case.
d. Nevertheless, the patient may call out at any time if he or she feels it necessary.
6. Have the patient mount onto the table in the supine position. Either before or right
after the patient lies down, set up any triggering devices or other monitoring
equipment that is to be used.
7. Center the patient in the head coil at the region where the key information is desired.
Make sure the head and neck are constrained to prevent motion.
Generally the patient’s head is fixed so that the head is horizontal (not tilted) and the neck
and head lie along the axis of the patient table.





8. If needed, place a pillow or other support under the knees to make the patient more
comfortable.
9. Use the centering light to position the patient (centered on the nasion) and put him
or her into the center of the magnet.
Once this step has been performed, so long as the patient does not move on the table, the
table itself can be moved and then replaced in the same position as before without
jeopardizing the positioning of one scan relative to another.
10. If the patient is unable to hold still, provide an appropriate sedative.
Sequence 1: Localizer
11. Run sequence 1 according to Table A3.1.2. The sagittal scout view is used to prescribe
the transverse or coronal planes.
Sequence 2: T1-weighted scan
12. Run sequence 2 according to Table A3.1.3.
Sequence 3: T2-weighted scan
13. Run sequence 3 according to Table A3.1.4.
Sequence 4: Fast FLAIR (fluid-attenuated inversion recovery) scan
14. Run sequence 4 according to Table A3.1.5.
Sequence 5: Post-contrast imaging
15. Remove the patient from the scanner. The patient should not move on the table.
Establish an intravenous line from which the contrast agent can be injected, and attach
this line securely to the patient so that movement into or out of the magnet will not
pull at the patient’s arm. Move the patient back into the scanner.
Table A3.1.2 Primary Clinical Imaging Parameters for Sequence 1
(T1-Weighted)
Patient position Supine
Scan type Spin echo
Imaging plane (orientation) Sagittal
Central slice or volume center Laser light centered on nasion
Echo time (TE) 11 msec (or select “minimum
full” echo time)
Receiver bandwidth (RBW) 10 kHz
Repeat time (TR) 500 msec
Flip angle (FA) 90°
Fields of view (FOVx, FOVy) 240 mm, 240 mm
Resolution (∆x, ∆y) 0.94 mm, 1.25 mm
Number of data points collected (Nx, Ny) 256, 192
Slice thickness (∆z) 5 mm
Number of slices 20 or as many as needed to cover
the region of interest
Slice gap 2 mm
Number of acquisitions (Nacq) 1
Swap read and phase encoding No
Saturation pulses Not applicable
Scan time 1 min, 28 sec




Table A3.1.3 Primary Clinical Imaging Parameters for Sequence 2
(T1-Weighted)
Patient position Supine
Scan type Spin echo
Imaging plane (orientation) Transverse
Central slice or volume center Laser light centered on nasion
Echo time (TE) 11 msec (or select “minimum
full” echo time)
Receiver bandwidth (RBW) 10 kHz
Repeat time (TR) 500 msec
Flip angle (FA) 90°
Fields of view (FOVx, FOVy) 240 mm, 240 mm
Resolution (∆x, ∆y) 0.94 mm, 1.25 mm
Number of data points collected (Nx, Ny) 256, 192
Display matrix (Dx, Dy) 256, 192
Slice thickness(∆z) 5 mm
Number of slices 20 or as many as needed to cover
the region of interest
Slice gap 2.5 mm
Number of acquisitions (Nacq) 1
Swap read and phase encoding Yes
Saturation pulses Not applicable
Scan time 1 min, 28 sec
Table A3.1.4 Primary Clinical Imaging Parameters for Sequence 3
(T2-Weighted)
Patient position Supine
Scan type Fast spin echo
Imaging plane (orientation) Transverse
Central slice or volume center Laser light centered on nasion
Echo time (TE) 102 msec (effective)
Receiver bandwidth (RBW) 16 kHz
Echo train length (ETL) 8
Repeat time (TR) 3600 msec
Flip angle (FA) 90°
Fields of view (FOVx, FOVy) 240 mm, 240 mm
Resolution (∆x, ∆y) 0.94 mm, 1.25 mm
Number of data points collected (Nx, Ny) 256, 192
Display matrix (Dx, Dy) 256, 192
Slice thickness (∆z) 5 mm
Number of slices 20 or as many as needed to cover
the region of interest
Slice gap 2.5 mm
Number of acquisitions (Nacq) 1
Swap read and phase encoding Yes
Saturation pulses Not applicable
Scan time ∼2 min





It is preferable to insert the line prior to imaging and to leave the patient in the magnet,
with no intervening motion, between the scans run before and after contrast agent injection
and those run after injection.
16. Leaving the patient in the magnet, inject the contrast agent, flush the line with 10 ml
saline.
A dose of 0.1 mmol/kg of contrast agent is usually given.
A delay in scanning may actually be beneficial when evaluating for metastases, which is
one of the reasons we scan in multiple planes after intravenous contrast administration.
17. Acquire the post-contrast images using the same parameters as sequence 2 (T1-
weighted).
In addition to the transverse plane, the coronal plane is routinely obtained, with the
following changes to the parameters in sequence 2: (a) flow compensation is on; (b) TE is
20 msec (prolonged due to flow compensation gradients); and (c) it is not necessary to
swap read and phase encoding directions. We also routinely obtain a third post-contrast
plane of imaging (sagittal) in patients requiring sedation and in all pediatric patients.
ALTERNATE
PROTOCOL
R/O HEMORRHAGIC METASTATIC DISEASE/METASTATIC MELANOMA
A small percentage of metastatic brain tumors will demonstrate evidence of hemorrhage.
These most commonly include melanoma, choriocarcinoma, renal cell, bronchogenic,
and thyroid carcinomas. The appearance will vary according to the stage of the hemor-
rhage (acute-chronic) on the T1-weighted and T2-weighted images (Thulborn et al., 1990;
Thulborn and Atlas, 1996; Atlas and Thulborn, 1998) and gradient-echo imaging demon-
strates evidence of hemorrhage that may not be seen with conventional spin-echo imaging
(Atlas et al., 1988). Intracranial metastatic melanoma (if melanotic) exhibits the typical
Table A3.1.5 Primary Clinical Imaging Parameters for Sequence 4 (Fast
FLAIR)
Patient position Supine
Scan type Inversion recovery fast spin echo
Imaging plane (orientation) Transverse
Central slice or volume center Laser light centered on nasion
Echo time (TE) 120 msec (effective)
Receiver bandwidth (RBW) 16 kHz
Echo train length (ETL) 8
Repeat time (TR) 10000 msec
Inversion time (TI) 2200 msec
Flip angle (FA) 180°
Fields of view (FOVx, FOVy) 240 mm, 240 mm
Resolution (∆x, ∆y) 0.94 mm, 1.25 mm
Number of data points collected (Nx, Ny) 256, 192
Display matrix (Dx, Dy) 256, 192
Slice thickness (∆z) 5 mm
Number of slices 20 or as many as needed to cover
the region of interest
Slice gap 2.5 mm
Number of acquisitions (Nacq) 1
Swap read and phase encoding Yes
Saturation pulses Not applicable
Scan time ∼5 min




imaging appearance of any paramagnetic lesion (Atlas et al., 1987), causing shortening
of T1 and T2 on MR images. However, the imaging appearance may be quite variable
depending on melanin content and hemorrhage.
Setup equipment and patient
1. Use the same equipment and perform patient setup as for the previous method (see
Basic Protocol).
Pre-contrast T1-weighted scan should be acquired in the same plane as the post-contrast
T1-weighted scan to look for intra-lesional enhancement.
Sequence 6: Gradient echo sequence




Brain metastases are common intracranial
tumors (Johnson and Young, 1996) affecting
between 80,000 and 170,000 individuals in the
United States per year (Davey, 1999). While
computed tomography (CT) may often be more
readily available and therefore the first exami-
nation performed for suspected intracranial pa-
thology, magnetic resonance imaging (MRI)
has proven to be invaluable in refining the
diagnosis. MRI with intravenous contrast pro-
vides the greatest sensitivity and exquisite ana-
tomical information for the detection of brain
metastases. The neuroanatomic location of me-
tastases and the associated edema and mass
effect determine the clinical presentation of the
patient. The most common primary sites of
brain metastases in adults include lung, breast,
skin (melanoma), and the gastrointestinal tract.
In younger patients, brain metastases often
arise from sarcomas and germ cell tumors.
Critical Parameters and
Troubleshooting
Intravenous contrast (gadolinium-DTPA) is
essential when evaluating the brain for the full
Table A3.1.6 Primary Clinical Imaging Parameters for Sequence 6 (Gradient
Echo)
Patient position Supine
Scan type 2-D gradient recalled echo
Imaging plane (orientation) Transverse
Central slice or volume center Laser light centered on nasion
Echo time (TE) 30 msec
Receiver bandwidth (RBW) 4 kHz
Repeat time (TR) 500 msec
Flip angle (FA) 15°
Fields of view (FOVx, FOVy) 240 mm, 240 mm
Resolution (∆x, ∆y) 0.94 mm, 1.25 mm
Number of data points collected (Nx, Ny) 256, 192
Display matrix (Dx, Dy) 256, 256
Slice thickness (∆z) 5 mm
Number of slices 20 or as many as needed to cover
the region of interest
Slice gap 2.5 mm
Number of acquisitions (Nacq) 1
Swap read and phase encoding Yes
Saturation pulses Not applicable
Scan time ∼2 min





extent of metastatic disease. A delay in scan-
ning is actually beneficial and at least two
planes of imaging should be obtained following
the administration of intravenous contrast.
Three planes of imaging (transverse, coronal,
and sagittal) should be acquired post-contrast
in patients requiring sedation and in all pediat-
ric patients. Not uncommonly, metastatic le-
sions (particularly to the cortex) are detected
solely on the post-contrast images, which is due
to similar signal characteristics with the adja-
cent brain tissue and the lack of surrounding
edema. Where small lesions (1 mm) can be
mistaken for vessels, the use of a first and
second dose of contrast can be used to distin-
guish lesions (more conspicuous after the sec-
ond dose) from vessels (no change in appear-
ance between doses).
Anticipated Results
The goal in evaluating the brain for metas-
tases is to demonstrate the total number of
lesions, and to depict the full extent of disease
burden in terms of edema, brain herniation and
hemorrhage. Magnetic resonance imaging of-
fers superb anatomical detail and tissue char-
acterization of brain metastases and provides
the greatest sensitivity for detecting lesions.
Time Considerations
The protocols detailed in this unit should
take ∼30 min to complete.
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